JADE DARE trial met co-primary and key secondary endpoints and demonstrated a safety profile consistent with previous studies for moderate to severe atopic dermatitis
The segment delivered strong sales growth of 20% YoY
Over 13 million people in Japan suffer from chronic kidney disease and this will transform treatment options
The company will manufacture the products at its US FDA approved oral dosage facility at Goa in India
Opaganib, a leading novel small molecule investigational oral pill in development for Covid-19, is a unique host targeted, dual antiviral and anti-inflammatory drug that acts on the cause and effect of the disease
Domestic business was up 41.9% YoY and 27.7% QoQ
It is the first branded generic alternative to Fostair 100/6 pMDI
Shanghai Roche Pharmaceuticals and Shanghai KeChow Pharma, entered into a cooperation agreement to improve market access of Zelboraf in China.
XELJANZ is the first and only Janus kinase (JAK) inhibitor approved in Europe for the treatment of polyarticular JIA and juvenile PsA and has received regulatory approval in four indications in the European Union, the most of any JAK inhibitor
This brings hope for patients suffering from all types of hernia, as the centre has a replenished armamentarium of technology and techniques to produce a good outcome
Subscribe To Our Newsletter & Stay Updated
